Pensioenfonds Rail & OV Makes New $37.37 Million Investment in Cencora, Inc. (NYSE:COR)

Pensioenfonds Rail & OV bought a new position in shares of Cencora, Inc. (NYSE:COR) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 153,798 shares of the company’s stock, valued at approximately $37,371,000. Cencora accounts for approximately 2.7% of Pensioenfonds Rail & OV’s investment portfolio, making the stock its 21st largest holding. Pensioenfonds Rail & OV owned 0.08% of Cencora as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Rise Advisors LLC acquired a new stake in shares of Cencora in the 1st quarter worth about $25,000. CVA Family Office LLC acquired a new stake in shares of Cencora in the 1st quarter worth about $34,000. Bruce G. Allen Investments LLC acquired a new stake in shares of Cencora in the 1st quarter worth about $43,000. Trust Co. of Vermont acquired a new stake in shares of Cencora in the 4th quarter worth about $62,000. Finally, Northwest Investment Counselors LLC acquired a new stake in shares of Cencora in the 1st quarter worth about $75,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Price Performance

Shares of NYSE:COR traded down $1.05 during trading hours on Wednesday, hitting $237.28. 851,715 shares of the company’s stock traded hands, compared to its average volume of 1,369,290. Cencora, Inc. has a 52 week low of $171.65 and a 52 week high of $246.75. The company has a debt-to-equity ratio of 3.41, a quick ratio of 0.53 and a current ratio of 0.89. The company’s fifty day simple moving average is $229.61 and its two-hundred day simple moving average is $227.60. The company has a market cap of $47.33 billion, a price-to-earnings ratio of 25.99, a price-to-earnings-growth ratio of 1.66 and a beta of 0.48.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, May 1st. The company reported $3.80 EPS for the quarter, topping the consensus estimate of $3.65 by $0.15. Cencora had a net margin of 0.67% and a return on equity of 268.67%. The company had revenue of $68.41 billion during the quarter, compared to analysts’ expectations of $70.60 billion. During the same period last year, the company posted $3.50 earnings per share. The business’s revenue for the quarter was up 7.8% on a year-over-year basis. As a group, equities analysts anticipate that Cencora, Inc. will post 13.44 EPS for the current fiscal year.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, May 24th. Shareholders of record on Friday, May 10th were issued a $0.51 dividend. This represents a $2.04 annualized dividend and a dividend yield of 0.86%. The ex-dividend date of this dividend was Thursday, May 9th. Cencora’s payout ratio is 22.32%.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. StockNews.com cut shares of Cencora from a “strong-buy” rating to a “buy” rating in a report on Thursday, May 2nd. Citigroup raised their target price on shares of Cencora from $265.00 to $280.00 and gave the company a “buy” rating in a research note on Tuesday, April 30th. Finally, Robert W. Baird raised their target price on shares of Cencora from $275.00 to $277.00 and gave the company an “outperform” rating in a research note on Thursday, May 2nd. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $233.90.

Insiders Place Their Bets

In other Cencora news, major shareholder Walgreens Boots Alliance, Inc. sold 1,859,390 shares of the firm’s stock in a transaction dated Wednesday, May 22nd. The shares were sold at an average price of $215.12, for a total value of $399,991,976.80. Following the completion of the transaction, the insider now directly owns 24,418,171 shares in the company, valued at $5,252,836,945.52. The sale was disclosed in a filing with the SEC, which is accessible through this link. In related news, COO Robert P. Mauch sold 57,564 shares of the firm’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $235.09, for a total transaction of $13,532,720.76. Following the completion of the sale, the chief operating officer now directly owns 24,412 shares in the company, valued at $5,739,017.08. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Walgreens Boots Alliance, Inc. sold 1,859,390 shares of the firm’s stock in a transaction that occurred on Wednesday, May 22nd. The stock was sold at an average price of $215.12, for a total transaction of $399,991,976.80. Following the sale, the insider now owns 24,418,171 shares of the company’s stock, valued at $5,252,836,945.52. The disclosure for this sale can be found here. Insiders sold a total of 1,956,675 shares of company stock worth $422,352,056 over the last ninety days. 15.80% of the stock is currently owned by company insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.